Research
Lactobacillus gasseri
30 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
A Randomized, Double-Blind, Placebo-Controlled Study on Probiotic Treatment for Halitosis: Novel Insights into Glucose and Phosphorus Metabolism.
A 12-week randomized, double-blind, placebo-controlled trial in South Korea evaluated the efficacy of Complex OK oral probiotics containing Lactobacillus gasseri and L. paracasei in reducing halitosis. The study found significant reductions in H₂S and total VSCs in the experimental group, along with a decrease in blood glucose and an increase in phosphorus levels, suggesting probiotics may mitigate bad breath through metabolic regulation.
Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.
A multi-centre, double-blind, parallel-group RCT with 210 healthy Japanese adults examined the effect of fermented milk containing Lactobacillus gasseri SBT2055 on abdominal adiposity. The study found significant reductions in abdominal visceral fat areas and other body measurements in groups consuming 10(7) and 10(6) cfu LG2055/g compared to control, suggesting the need for constant consumption to maintain effects.
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy.
RCT of 229 patients with H. pylori infection comparing standard triple therapy to triple therapy plus L. gasseri-containing yogurt. The yogurt-plus-triple group showed improved eradication rates of H. pylori, particularly in clarithromycin-resistant strains.
Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection.
RCT investigating the long-term administration of Lactobacillus gasseri OLL2716 (LG21) in 440 asymptomatic pre-school children for the eradication or prevention of Helicobacter pylori infection. In the eradication arm, 29.3% of H. pylori positive children were negative at 12 months. In the prevention arm, 4.1% of the active group and 8.1% of the placebo group were HpSA positive at 12 months.
Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial.
RCT of 479 healthy adults supplemented with Lactobacillus gasseri, Bifidobacterium longum, and B. bifidum for at least 3 months. The probiotic group showed reduced severity and duration of common cold symptoms, with increased fecal lactobacilli and bifidobacteria.
CECT 30648 shows probiotic characteristics and colonizes the vagina of healthy women after oral administration.
RCT assessing the vaginal colonization of probiotic strain CECT 30648 in 48 healthy women after oral administration. CECT 30648 showed broad-spectrum antimicrobial activity, colonized the vaginal tract in over 55% of participants, and modulated vaginal microbiota toward a lactobacillus-dominated status, suggesting potential to promote vaginal health.
Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.
RCT investigating the effects of Lactobacillus gasseri on functional constipation in 40 women. The study found that Lactobacillus gasseri significantly reduced abdominal pain and showed a tendency for increased complete spontaneous bowel movements.
The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study.
RCT evaluating the efficacy of Lactobacillus gasseri OLL2716 on functional dyspepsia in H. pylori-uninfected individuals. The L. gasseri OLL2716 group showed more positive impressions regarding gastric symptoms and a higher elimination rate for major FD symptoms compared to placebo.
Yogurt Containing Lactobacillus gasseri Mitigates Aspirin-Induced Small Bowel Injuries: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
This prospective, randomized, double-blind, placebo-controlled trial evaluated the effects of Lactobacillus gasseri OLL2716 (LG) on aspirin-induced small bowel injuries in 64 patients. The LG group had significantly fewer small bowel mucosal breaks and improved gastrointestinal symptoms compared to the placebo group after 6 weeks.
The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome.
RCT investigating the effects of Lactobacillus gasseri CP2305 on quality of life and clinical symptoms in IBS patients. CP2305 improved IBS severity index scores and reduced health-related worry, with changes in intestinal microbiota and gene expression related to EIF2 signalling.
Lactobacillus gasseri SBT2055 suppresses fatty acid release through enlargement of fat emulsion size in vitro and promotes fecal fat excretion in healthy Japanese subjects.
The study evaluated the effects of Lactobacillus gasseri SBT2055 (LG2055) on fat hydrolysis and fecal fat excretion. In vitro, LG2055 suppressed lipase activity and increased fat emulsion droplet size. In a double-blind, randomized, placebo-controlled trial, LG2055 increased fecal fat excretion in healthy Japanese subjects.
Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis.
Randomized, double-blind, placebo-controlled study on school children with asthma and allergic rhinitis, testing daily supplementation with Lactobacillus gasseri A5 for 8 weeks. Results showed significant improvements in pulmonary function, PEFR, and clinical symptom scores for asthma and AR, along with reduced production of TNF-α, IFN-γ, IL-12, and IL-13 by PBMCs.
Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial.
RCT evaluating the effects of Lactobacillus gasseri SBT2055 on abdominal adiposity and body measures in adults with obese tendencies. The probiotic group showed significant reductions in abdominal fat, body weight, BMI, waist, and hip measurements compared to the control group.
Efficacy of oral administration of a heat-killed Lactobacillus gasseri OLL2809 on patients of Japanese cedar pollinosis with high Japanese-cedar pollen-specific IgE.
A randomized, double-blind, placebo-controlled trial assessed the effects of oral administration of heat-killed Lactobacillus gasseri OLL2809 on Japanese cedar pollinosis symptoms. While no overall differences were observed, subgroup analysis showed improvement in nasal symptoms and allergy-related markers in subjects with high CAP-RAST scores.
Immunomodulation in gut-associated lymphoid tissue of neonatal chicks by immunobiotic diets.
RCT studying the effects of immunobiotic lactic acid bacteria on gut-associated lymphoid tissue in neonatal chicks. L. gasseri TL2919 and L. jensenii TL2937 diets increased T cell-related mRNA expression, suggesting potential as immunomodulators without affecting growth performance.
Therapeutic value of a Lactobacillus gasseri and Bifidobacterium longum fixed bacterium combination in acute diarrhea: a randomized, double-blind, controlled clinical trial.
A multicenter, parallel-group, randomized, double-blind, active-controlled clinical trial assessed the efficacy of a fixed bacterium combination of Lactobacillus gasseri and Bifidobacterium longum in treating acute diarrhea in 169 outpatients. The combination was found to shorten the duration and decrease the severity of diarrhea, with a higher proportion of patients achieving complete recovery compared to a mono-bacterium treatment.
Dietary deprivation of fermented foods causes a fall in innate immune response. Lactic acid bacteria can counteract the immunological effect of this deprivation.
RCT studying the effects of dietary deprivation of fermented foods on immune response in healthy volunteers. Deprivation led to decreased faecal lactobacillus counts and phagocytic activity in leukocytes. Probiotic products containing Lactobacillus strains counteracted the fall in immune response, with probiotics being more effective than standard yogurt.
The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans.
RCT investigating the immune effects of a fermented product containing Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711 compared to standard yogurt in healthy humans. The new product increased phagocytic cells, NK cells, and IgA concentrations, enhancing immunity more than the control yogurt.
Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 Ingestion Induces a Less Inflammatory Cytokine Profile and a Potentially Beneficial Shift in Gut Microbiota in Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
This randomized, double-blind, placebo-controlled, crossover study investigated the effects of a probiotic mixture on older adults. The probiotic maintained CD4+ lymphocytes, increased interleukin-10 levels, and induced a beneficial shift in gut microbiota, suggesting a less inflammatory cytokine profile and improved gut health.
Heat-killed Lactobacillus gasseri can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study.
This double-blind, placebo-controlled clinical trial tested the effects of heat-killed Lactobacillus gasseri TMC0356 on immune response in 28 elderly subjects. The study found that TMC0356 increased the number of CD8(+) T cells and reduced CD28 expression loss in CD8(+) T cells, suggesting enhanced natural defense mechanisms against infections.
Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects.
Single-blind, placebo-controlled, within-subject, repeated-measure intervention trial with 20 Japanese subjects with hypertriacylglycerolemia. The study found that consumption of Lactobacillus gasseri SBT2055 reduced postprandial and fasting serum non-esterified fatty acid levels, suggesting a potential reduction in the risk for obesity and type 2 diabetes mellitus.
Effects of Lactobacillus gasseri OLL2809 and α-lactalbumin on university-student athletes: a randomized, double-blind, placebo-controlled clinical trial.
RCT evaluating the effects of Lactobacillus gasseri OLL2809 and α-lactalbumin on university-student athletes. LG2809 prevented reduced natural killer cell activity and improved mood, while LG2809 + α-lactalbumin alleviated minor resting fatigue, supported by reductions in serum reactive oxygen metabolites and transforming growth factor β1 levels.
A synbiotic containing Lactobacillus gasseri [corrected] CHO-220 and inulin improves irregularity of red blood cells.
This randomized, double-blind, placebo-controlled study investigated the effect of a synbiotic product containing Lactobacillus gasseri CHO-220 and inulin on red blood cell irregularity in hypercholesterolemic subjects. The synbiotic improved RBC shape, reduced the cholesterol:phospholipids ratio by 47.02%, and altered fatty acid composition, increasing membrane fluidity over 12 weeks.
Lactobacillus gasseri [corrected] CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters.
This randomized, double-blind, placebo-controlled study investigated the effect of a synbiotic product containing Lactobacillus gasseri CHO-220 and inulin on lipid profiles in hypercholesterolemic men and women. The synbiotic reduced plasma total cholesterol and LDL-cholesterol by 7.84% and 9.27%, respectively, over 12 weeks, suggesting an atheropreventive characteristic.
A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy.
Double-blinded, randomized controlled trial with 44 allergic children comparing a probiotic dairy product containing Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711 to conventional yogurt. The probiotic product induced a significant decrease in plasma IgE levels and an increase in CD4(+)/CD25(+) T regulatory cells, as well as enhanced innate immune parameters.
[Beneficial effects of consumption of a dairy product containing two probiotic strains, Lactobacillus coryniformis CECT5711 and Lactobacillus gasseri CECT5714 in healthy children].
RCT involving 30 healthy children to assess the effects of a probiotic product containing Lactobacillus coryniformis CECT5711 and Lactobacillus gasseri CECT5714. The study found improved intestinal flora, reduced faecal cytotoxicity, increased inhibition of pathogen adhesion, and enhanced IgA concentration, indicating positive effects on gut health and immunity.
Preliminary human study for possible alteration of serum immunoglobulin E production in perennial allergic rhinitis with fermented milk prepared with Lactobacillus gasseri TMC0356.
RCT administering fermented milk with Lactobacillus gasseri TMC0356 to 15 subjects with high serum IgE levels and perennial allergic rhinitis. The intervention significantly reduced serum total IgE concentration and increased Th1 cells, suggesting potential immune modulation.
Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults.
A randomized, double-blind, placebo-controlled trial with 30 healthy adults tested the effects of a fermented product containing Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711 on intestinal function. The probiotic group showed increased fecal lactic acid bacteria, improved production of short chain fatty acids, fecal moisture, and stool frequency and volume, indicating enhanced intestinal function.
Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans.
RCT of 31 subjects infected with Helicobacter pylori ingesting yogurt containing Lactobacillus gasseri OLL2716 (LG21) daily for 8 weeks. Significant improvement in H. pylori suppression and reduction in gastric mucosal inflammation was observed.
Survival of yogurt-containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects.
RCT examining the effect of yogurt cultures and Lactobacillus gasseri (ADH) on bacterial enzyme activity in the gastrointestinal tract of 33 elderly subjects. ADH was found to survive passage through the gastrointestinal tract and significantly reduced fecal bacterial enzyme activity.